Shirali Anushree C, Bia Margaret J
Division of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Clin J Am Soc Nephrol. 2008 Mar;3(2):491-504. doi: 10.2215/CJN.05081107. Epub 2008 Feb 20.
Cardiovascular disease is a major cause of graft loss and the leading cause of death in renal transplant recipients. Although there are robust data on the frequency of risk factors and their contributions to cardiovascular disease in this population, few trials have demonstrated the benefit of modifying these risk factors to reduce cardiovascular events. Nevertheless, it is widely accepted that the clinical acumen filtered through the best available studies in the general population be used to treat individual renal transplant recipients given their high cardiovascular mortality. Transplant task forces and the Kidney Disease Outcomes Quality Initiative have created guidelines for this purpose. This review examines the data available for prevention and treatment of major risk factors contributing to cardiovascular disease in renal transplant recipients. The contribution of immunosuppressive agents to each risk factor and the evidence to support lifestyle modification as well as drug therapy are examined. Reducing cardiovascular risk factors requires an integrative approach that is best accomplished by a team of health care professionals. It creates a significant challenge but one that must be met if allograft survival is to improve.
心血管疾病是肾移植受者移植物丢失的主要原因及死亡的首要原因。尽管有关于该人群中危险因素的发生频率及其对心血管疾病影响的有力数据,但很少有试验证明改变这些危险因素可减少心血管事件。然而,鉴于肾移植受者心血管疾病死亡率高,通过普通人群中现有最佳研究得出的临床判断用于治疗个体肾移植受者已被广泛接受。移植工作组和肾脏疾病预后质量倡议组织已为此制定了指南。本综述审视了肾移植受者中导致心血管疾病的主要危险因素的预防和治疗的现有数据。研究了免疫抑制剂对各危险因素的影响以及支持生活方式改变和药物治疗的证据。降低心血管危险因素需要一种综合方法,这最好由一组医疗保健专业人员来完成。这带来了巨大挑战,但如果要提高同种异体移植物存活率,就必须应对这一挑战。